×

14 November 2017 

CLEAN INVEST AFRICA PLC

(???CIA??? or the ???Company???)

Admission to the NEX Exchange Growth Market

Clean Invest Africa Plc, an Investment Vehicle for the purpose of identifying investment opportunities and acquisitions in renewable and clean energy projects/companies or alternative technologies that are used in a socially and environmentally responsible way that will aid the development of the African continent, with the intention of building a diversified portfolio of assets, is pleased to announce that trading in its Ordinary Shares will commence at 8:00 a.m. today on the NEX Exchange Growth Market (???Admission???), under the ticker CIA and ISIN number GB00BF52QX07.

On Admission, the Company will have net funds of ??512,440 and there will be 156,100,000 Ordinary Shares in issue, which rank pari passu in all respects.

Overview

The Company???s primary strategy is to acquire interests in and to own, assist and manage clean energy companies and projects, including renewable energy projects and projects that create environmental benefits through greenhouse gas emission reductions. Renewable energy can generally be defined as energy (such as electricity, transportation fuels, sources of process heat, etc.) derived from resources that are regenerative or for practical purposes cannot be depleted. Renewable energy technologies may be broadly divided into two categories: (1) production of electricity, from sources such as wind, solar, geothermal, hydro, biomass, or municipal wastes; and (2) production of transportation fuels, such as ethanol and biodiesel. Renewable energy is generally considered to involve relatively less environmental impact than traditional sources of energy. The combustion of renewable fuels typically results in a reduction of greenhouse gases (CO2, methane, nitrous oxide, hydrofluorocarbons, perfluorocarbons and sulphur hexafluoride) produced per unit of energy when compared with traditional sources of energy.

Website: www.cleaninvestafrica.com
Market capitalisation at 1p is ??1,561,000

Samuel Preece, Executive Director of CIA, said: ???The renewable and clean energy requirements in African countries present CIA with an economic opportunity. Increases in the price of fossil fuels have led to a significant improvement in the cost competitiveness of renewable energy versus traditional, non-renewable, sources. We are actively seeking investment opportunities and are pleased to be investing in a space where renewable energy resources may greatly reduce emissions of greenhouse gases.???

Details of Directors

The full names of the Directors of the Company and positions are as follows:

Samuel Toby Preece, Executive Director (aged 41)

Samuel has over 20 years of environmental consulting experience, having completed over 1,500 projects in Europe, Asia, Australia, Middle East, Canada, USA and South America as well as across Africa.

Samuel has overseen the technical evaluation and permitting of alternative energy projects across the UK, Ireland, Europe and Africa. These projects include a wide range of energy technologies including on and offshore wind, solar, tidal, hydroelectric, geothermal, ground source heat pumps, pumped storage, waste to energy, anaerobic biodigestion, and gas to power, in a number of  applications.

Samuel spent five years as an in-house technical specialist at an international construction contractor, Laing O???Rourke, working on projects in the technology and energy sectors.

Samuel was previously a director responsible for the UK and Ireland???s environment business line of AECOM, a business that had revenues of approximately US$17.4 billion in the fiscal year to 2016. In this role at AECOM, Sam advised national and multinational clients on the technical feasibility and licencing and permitting of their energy, technology and land asset projects. These projects include energy projects across Africa.

Samuel has access to a network of environmental and energy technical experts located across Africa with local knowledge and technical expertise and currently supports investors and companies looking to grow and seek investment in business and projects in Africa. These currently include renewable energy, green technology projects in southern and sub-Saharan Africa. Sam also advises on Environmental, Social and Governance risks and opportunities for investors, companies and financial institutions including in the energy sector.

Andrew Paul Matharu, Independent Non–Executive Director (aged 48)

Andrew has over 22 years' experience in the oil & gas sector and commenced his career as a Petroleum Engineer with Chevron and Kerr-McGee Oil. Andrew has extensive experience of advising small and mid-cap oil & gas companies in equity capital markets following a variety of corporate finance and institutional equity roles at Cazenove, Bridgewell Securities and Westhouse Securities. His most recent role was in Corporate Development with the Africa-focussed AIM-listed explorer, Tower Resources plc, where he was involved in a number of corporate and asset M&A transactions and capital raisings.

Andrew holds a BEng degree in Chemical Engineering from University of Sheffield, a PhD in Chemical Engineering from the University of Cambridge and is a Chartered Engineer.

Noel Lyons, Non-Executive Director (aged 52)

Noel started his career in the accounting profession and progressed from there to management and director level within various organisations. He has worked for such companies as Amoco/BP, Coca Cola, Kentz Corporation Plc and Oilinvest International, and has worked in diverse locations such as Africa and The Middle East.

Noel has been involved in several listings on AIM and the NEX Exchange Growth Market in both a management and advisory capacity, including as co-founder and, initially, as a non-executive director of Karoo Energy plc. Noel has an MBA and masters in Accounting and Finance.

Directors??? Interests

On Admission the interests of the Directors and their immediate families and, so far as they are aware having made due and careful enquiries, of persons connected with them (all of which are beneficial, unless otherwise stated) (so far as is known to the Directors, or could with reasonable diligence be ascertained by them) (within the meaning of sections 252 to 254 of the UK Companies Act 2006) in the Issued Share Capital are as follows:

Director	Number of Ordinary Shares on Admission	% of Issued Share Capital
Samuel Preece	1,200,000	0.77
Andrew Matharu	1,200,000	0.77
Noel Lyons	9,800,000	6.28

 

Significant Shareholders

In addition to the Directors holdings disclosed above, the Company has been notified or is aware of the following holdings which will, following Admission, represent more than 3 per cent. of the Issued Share Capital or voting rights of the Company:

Name	Number of Ordinary Shares on Admission	% of Issued Share Capital
Ren?? Carayol	9,800,000	6.28
Jim Nominees	132,500,000	84.88

 

The Directors of the Company are responsible for the content of this announcement.

For further information, please contact:

The Company
Sam Preece	+ 44 (0) 20 3130 0674
NEX Exchange Corporate Adviser Peterhouse Corporate Finance Limited
Guy Miller/Mark Anwyl	+44 (0) 20 7469 0936

Close

×

Neville Registrars is delighted to welcome Clean Invest Africa Plc as the newest addition to its list of client companies.

Clean Invest Africa is an Investment Vehicle that will focus on acquiring stakes in clean energy companies, remediation / restoration technologies, waste to energy technologies and other clean energy related projects throughout Africa. 

Further information can be found on the Company's website: https://www.cleaninvestafrica.com/

 

Close

×

RNS Number : 2484W

Concepta PLC

13 November 2017

 

13 November 2017

 

Concepta plc

("Concepta" or the "Company")

£600,000 sales order confirmed

Concepta plc (AIM: CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, is pleased to announce that the Company has received formal confirmation of a £600,000 sales order (the "Order") (RMB 5,058,196).

The order for 5,200 of Concepta's myLotus meters was previously announced on 6 November 2017 and has been placed by ShanDong WeiHai HaiChen Pharmaceutical Co. Ltd in China. Revenues from this order will be realised in Q4 2017.

The order has been received from ShanDong WeiHai HaiChen Pharmaceutical Co. Ltd based in WeiHai City, ShanDong Province and covers the territories Beijing, Shanghai, ShanDong Province and Henan Province. 

 

Erik Henau, CEO of Concepta plc said: "I am very pleased to be able to confirm the receipt of this significant order for our myLotus product. We are now starting to see our considerable investment in relationship building, marketing, and setting up manufacturing, logistics and distribution begin to bear fruit in China. We expect to be able to announce further orders in the coming months and I look forward to updating shareholders in due course."

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Enquiries:

 

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

 

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

 

Founded in 2013, Concepta has developed a revolutionary flagship product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive.  

 

MyLotus is the only consumer product which allows both quantitative and qualitative measurements of measurement of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.  Competitor products currently only allow qualitative measurement and are based on the 'average woman'.  

 

Concepta has a defined route to market for its new 'My Lotus' product with Regulatory approvals for launch in China in place for 2016 and CE-Marking for UK and Europe to follow in 2018 where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCFFAEFEFWSELF

Close

×

RNS Number : 8341V

N4 Pharma PLC

08 November 2017

 

08 November 2017

N4 Pharma Plc

("N4 Pharma" or the "Company")

Results of latest nuvec® pre-clinical study

N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces the results of the latest study it has conducted for its nuvec® silica nanoparticles ("SiNPs") delivery system.

As well as investigating tolerability, the objective of this study (funded via a biomedical Catalyst Grant) was to determine the in-vivo capacity for the Company's SiNPs to deliver DNA to generate local expression of a protein. This is a key indicator as to whether a vaccine delivery system is likely to successfully generate an immune response.  The Company completed two tests in this study, the first was an injection directly into a cancerous tumour and the second was a subcutaneous injection; two routes of administration typically used for vaccination.

In conclusion, a single injection of the SiNPs is effective in delivering DNA to generate localised protein expression at the site of the injection and draining lymph nodes and release cytokines into the systemic circulation. These are all crucial elements for successful cancer therapy treatment.  No tolerability issues were encountered for the duration of the study.

 

Following these results, further in-vivo studies will be conducted to demonstrate the capability of the Company's SiNPs to deliver specific antigens to promote an adaptive immune response (i.e. as a vaccine) or to deliver functional proteins that can have a biological effect and to undertake comparison studies showing how the Company's SiNPs compare to lipid nanoparticles, which are widely used as delivery systems for cancer vaccines and therapies.

 

Nigel Theobald, CEO of N4 Pharma, commented:

"As well as preparing to take our sildenafil reformulation into clinic, we have been scoping out the potential for our nuvec®  delivery system and continue to make encouraging progress demonstrating its capability. This signifies another prominent step forward on the road to commercialising nuvec® .

We now have evidence that our  SiNPs have many desirable features for use in either a vaccine approach or to deliver therapeutic proteins to tissues and are uncovering key commercial advantages compared to lipid nanoparticles. This increases the scope of nuvec's® application which in turn enhances the value of the technology to potential commercial partners.  

The value of the global nanotechnology drug delivery market is forecast to grow from $4.1 billion in 2014 to $11.9 billion in 2023*.

As nuvec® continues to meet its technical targets, it becomes very clear that we have the potential to become a significant player in this growing market. We will continue its development to determine how best to compete and to take the technology forward."

* source: Transparency Market Research July 2014

 

 

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO,	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: +44(0)207 601 6100
Beaufort Securities Elliot Hance	Tel: +44(0)207 382 8300
Alma PR Josh Royston Robyn Fisher	Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

 

Glossary

Silica nanoparticles (SiNPs)	Small manufactured structures, measured in a narrow size range of nanometres, that are derived from silicon.
Cytokines	Cytokines are cell signalling molecules that aid cell to cell communication in immune responses and stimulate the movement of cells towards sites of inflammation, infection and trauma.
Antigen	An antigen is any substance that causes your immune system to produce antibodies against it. This means your immune system does not recognize the substance, and is trying to fight it off.
Lipid nanoparticles	Lipid nanoparticles are small particles, measured in nanometres, formed through either the complexation or encapsulation of nucleic acids with cationic lipids.
Subcutaneous injection	A subcutaneous injection is a method of administering medication. Subcutaneous means under the skin. In this type of injection, a short needle is used to inject a drug into the tissue layer between the skin and the muscle. Medication given this way is usually absorbed more slowly than if injected into a vein, sometimes over a period of 24 hours.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

RESQDLFBDFFFFBB

Close

×

RNS Number : 9281V

Character Group PLC

08 November 2017

 

 

 

LONDON: Wednesday, 8 November 2017

 

 

The Character Group plc

("Group", "Character" or the "Company")

Designers, developers and international distributors of toys, games and giftware

 

"2 in the Dream Toys Dozen for Character"

 

 

The Board of The Character Group plc (AIM: symbol: CCT.L) is very pleased to report that its principal trading subsidiary, Character Options Limited ("Character Options") has once again featured strongly in the prestigious best toys of the year list, 'Dream Toys'.

 

Each year, the Toy Retailer Association issues a highly-esteemed list of the 'Dream Toys' from its annual event in London.  Based on the opinions of large chain retailers, small multiples and independent retailers across the UK, the Dream Toys' dream dozen is regarded as the most informative insight into what children want for Christmas.

Dream Toys 2017 opened at 7am today (8 November 2017) and the Dream Toys' dream dozen results announced, revealing that Character Options was once again amongst the successful 12 with both Stretch Armstrong and Laser X toys being in the top rankings.

In addition to the official top 12 Dream Toys, the event also sees the Toy Retailers Association announce other top lists, based on categories such as creative toys, pre-school and games.  Character Options is also proud to have its, Little Live Pets Ladybug, Little Live Pets My Dream Kitten, and Soundmoovz products in these lists.

Jerry Healy, Group Marketing Director at Character, commented,

"We are delighted to once again feature so prominently at the Dream Toys event.  The Original Stretch Armstrong continues to go from strength to strength and its confirmation as a Dream Toy reflects the success of the entire Stretch portfolio, which also includes Vac Man, Fetch and Stretch Monster.  With Laser X, we have experienced a high volume of sales since its launch in summer and we expect it to be in the running as a top toy of the year."

"Since the first Dream Toys in 2010, the winning toys have gone on to become the best-selling and most-wanted toys for Christmas, and Character Options has been foremost in the lists each year since".

Jon Diver, Character's Joint MD added:

"To be recognised once again and receive recognition for our products is fantastic for the Company – the team is dedicated to and focused on developing, marketing and distributing innovative and exciting toys that meet the high expectations that our customers and the consumer demand both in terms of quality and value."

"We are having a great reception to our product portfolio from both the retailers and media.  We have a great range of established brands and these will be added to by the introduction of new product lines, all of which we hope will deliver a very exciting season ahead for the business."

Product ranges can be viewed at www.character-online.co.uk

 

ENQUIRIES
The Character Group plc Jon Diver, Joint Managing Director Kiran Shah, Joint Managing Director and Group Finance Director Jerry Healy, Group Marketing Director
Office:     +44 (0) 208 329 3377 Mobile:   +44 (0) 7831 802219 (JD) Mobile:  +44 (0) 7956 278522 (KS) Email: [email protected] FTSE sector:  leisure: FTSE AIM All-share: symbol: CCT.L: Market cap: £87m
Panmure Gordon (Nominated Adviser and Joint Broker) Andrew Godber, Investment Banking Tom Salvesen, Corporate Broking Tel:  +44 (0) 20 7886 2500
Allenby Capital Limited (Joint Broker) Nick Athanas Katrina Perez Tel:  +44 (0) 20 3328 5656
Evolution PR (Trade and consumer media) Michele Bates Tel: +44 (0) 01327 227010 Email: [email protected]
TooleyStreet Communications Limited (Investor and media relations) Fiona Tooley Tel:  +44 (0) 7785 703523 Email: [email protected]

 

 

Market Abuse Regulation (MAR)

The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

STRBPBBTMBTMBRR

Close

×

RNS Number : 7101V

Nasstar PLC

07 November 2017

 

Nasstar plc

 

("Nasstar", "Company" or "Group")

 

Significant Contract Win

 

Nasstar (stock code: NASA), a provider of hosted managed and cloud computing services, is pleased to announce that following a successful proof of concept with a global media company it has secured a three year contract to deliver a fully managed public/private Hybrid cloud solution to a global workforce of 1,000 users. The contract is expected to generate at least £2.1m of revenues over the three-year term, with up to £3.3m of revenues possible if client user numbers remain as they are today. The contract will go live during a phased migration project which is expected to be fully complete by the end of June 2018.

 

This contract further ratifies the Company's leading approach and innovation in Hybrid cloud solutions. Nasstar will deliver a fully managed service to the 1,000 users that integrates Microsoft's public cloud solutions with the Nasstar private cloud hosted desktop. This is made possible because the Group holds a tier one agreement to sell Microsoft's cloud offerings and has Shared Computer Activation (SCA) accreditation. This SCA accreditation enables Nasstar to integrate O365 fully with hybrid platforms.  Nasstar are one of only a few Microsoft partners that hold such accreditation today. This has enabled the Group to further integrate the O365 offering into its hosted desktop solution, embracing the innovations of O365 as a clear differentiator over its competitors.

 

Nasstar CEO, Nigel Redwood commented:

 

"This represents a significant win for Nasstar which was made possible by our innovation in developing a comprehensive managed service business, embracing both the public and private cloud offerings to deliver the best of both worlds to our clients. The investment we have made in our 24×7 capabilities, not only in support but also in projects, was a significant factor in enabling Nasstar to meet the demands of a global business such as this.

 

A contract of this size is testament to our growing ability to service larger clients and a further endorsement of the 'Nasstar 10-19' programme".

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

For further information, please contact:-

 

Nasstar plc                                                                   +44 (0) 1952 225 000

Nigel Redwood, Chief Executive Officer               

Niki Redwood, Finance Director                          

 

finnCap Limited (Nominated Adviser & Broker)               +44 (0) 20 7220 0500

Julian Blunt, James Thompson (Corporate Finance)

Stephen Norcross (Corporate broking)

 

About Nasstar plc

Nasstar (www.nasstar.com) and its wholly owned operating businesses provide hosted managed and cloud computing services, integrating private and public clouds supplying a robust, secure and stable hosted Information Technology service to business customers. The Group provides a true end to end service for clients providing them with enhanced IT performance and greater cost control over their IT function. The Group owns its primary data centre, is head quartered in Telford with regional offices in Northampton, London and Bournemouth whilst 24 x 7 support is delivered from its Auckland office in New Zealand. Nasstar is an accredited Microsoft Gold Partner, is the 2016 Citrix Networking Partner of the Year and is certified to ISO 27001.

 

Nasstar specialises in building bespoke cloud hosted services to manage a client's entire application set, tailor made to suit specific industries, designing public, private and hybrid cloud solutions to meet the objectives of the client. The solution is a highly scalable service that provides benefits including "Anywhere Access" to computing; a standardised corporate solution that can be accessed globally in multiple languages; generating cost savings when compared to the traditional IT ownership model whilst replacing capital expenditure with a simple usage based payment model.

 

Nasstar (AIM:NASA) was founded in 1998, admitted to AIM in December 2005, acquired e-know.net Limited in a reverse takeover in January 2014, Kamanchi Limited in July 2014, VESK in October 2015 and Modrus Limited in September 2016.

 

Ends

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTQQLFBDFFEFBQ

Close

×

RNS Number : 5799V

First Derivatives PLC

06 November 2017

 

6 November 2017

 

First Derivatives plc

("FD" or the "Group")

 

Kx selected by Red Bull Racing for Sensor Analytics

 

FD (AIM:FDP.L, ESM:FDP.I) announces that it has been selected by Red Bull Racing as a team supplier for the use of its Kx technology to analyse sensor data from its Formula 1 vehicles. Initially, Kx will be deployed for the analysis of wind tunnel data, a critical element in the development of faster, more competitive F1 cars.

 

It is intended that Red Bull Racing will use Kx for a range of purposes including wind tunnel experiments and the analysis of in-race data to enable real-time decisions during Grand Prix races. With over 100 sensors on a typical F1 car, Kx technology is able to capture, integrate and analyse vast quantities of data to provide real-time actionable insights. These insights and subsequent team and driver action have the potential to make the difference to race results and safety, on cars travelling at up to 300 kilometres per hour.

 

Kx's compact footprint and powerful analytics, which make it ideal for the challenging requirements of F1 cars, provides the potential to open additional markets where real-time analysis of large volumes of sensor data is a critical requirement. This includes the growing vehicle analytics market, where Gartner predicts that by 2020 there will be 250 million connected vehicles on the road, as well as extending to industries such as discrete manufacturing, logistics and utilities, an opportunity BGC estimates to be valued at $80bn per annum by 2020. 

 

Brian Conlon, Chief Executive Officer of Kx, commented: "We at Kx are delighted to work with Red Bull Racing. Both companies are associated with power, speed, precision engineering and innovation. Over the years F1 has proven itself as an ideal testing ground for disruptive technologies and we look forward to bringing the power of Kx to bear in high-value complementary markets."

 

 

Enquiries

For further information please contact:

First Derivatives plc Brian Conlon, Chief Executive Officer Graham Ferguson, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44(0)28 3025 2242 www.firstderivatives.com
Investec Bank plc (Nominated Adviser and Broker) Carlton Nelson Sebastian Lawrence	+44 (0)20 7597 4000
Goodbody (ESM Adviser and Broker) Linda Hickey Finbarr Griffin	+353 1 667 0420
FTI Consulting Matt Dixon Dwight Burden Darius Alexander Niamh Fogarty	+44 (0)20 3727 1000

About FD

FD is a global technology provider with 20 years of experience working with some of the world's largest finance, technology, retail, pharma, manufacturing and energy institutions. The Group's Kx technology, incorporating the kdb+ time-series database, is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. Kx delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications across multiple industries. FD operates from 14 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 1,800 people worldwide.

 

For further information, please visit www.firstderivatives.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAMMMGMNFNGNZM

Close

×

RNS Number : 5896V

Veltyco Group PLC

06 November 2017

 

 

6 November 2017

 

Veltyco Group plc

("Veltyco", the "Company" or the "Group")

 

EiG Award eSports.com

 

 

The board of Veltyco is proud to announce that eSports.com was awarded the prestigious EIG award of best start-up during the leading EiG (Excellence in iGaming) conference held last week in Berlin.
 

eSports.com was set up to build an online community that produces engaging and exclusive content aimed at esports enthusiasts, including an esports shop (for merchandise, hardware or in-game items), guides, tutorials and coaching lessons from users.

David Mathewson, Chairman, commented: "Veltyco is delighted to see the recognition that eSports.com is receiving in the market. We recently announced the partnership with eSports.com and this further validates the importance of this strategic partnership."

 

 

For further information, please contact:

 

Veltyco                                                                                                        +44 (0)16 2460 5764

David Mathewson, Chairman                                    

Marcel Noordeloos, CFO

 

Strand Hanson Limited (Nominated Adviser)                              +44 (0)20 7409 3494

James Harris

Richard Tulloch

James Dance

 

Northland Capital Partners Ltd (Broker)                                          +44 (0)20 3861 6625

Tom Price

IFC Advisory (Financial PR &IR)                                                           +44 (0)203 053 8671

Graham Herring

Tim Metcalfe

Miles Nolan

 

About Veltyco

Veltyco is a group of companies primarily focused on generating marketing leads and entering into marketing contracts for the activities of various partners in the gaming industry.  Veltyco focuses on complementary activities under one umbrella, leveraging its historical cash generative activities of marketing online casinos and sports betting. 

Website: http://www.veltyco.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUGGGAGUPMGRA

Close

×

RNS Number : 1607V

Osirium Technologies PLC

01 November 2017

 

 

1 November 2017

 

Osirium Technologies plc

 

("Osirium" or "Group")

 

Contract win with one of Europe's leading private equity firms

 

Osirium Technologies plc (AIM: OSI.L), a UK headquartered cyber-security SaaS provider, is pleased to announce a new customer win with one of Europe's leading private equity firms.  The contract will run over an initial twelve-month term.

 

The customer primarily invests in three areas, private equity, real estate and infrastructure.  Since 1994, the Group has invested over €16 billion in 34 businesses with an aggregate enterprise value of over €48 billion.

 

The Group has appointed Osirium to deliver its full PxM product offering of Privileged Account Management and Privileged Task Management modules with associated consultancy services.  The focus has been to tighten security controls and access and introduce reporting and auditing of systems and applications.

 

David Guyatt, Chief Executive Officer, commented: "We are delighted to secure this major new financial services customer and a further 'land and expand' licensing deployment.   With the recent and highly-publicised spike in cyber terrorism and increasing numbers of businesses suffering devastating data breaches, they wanted to ensure that their customers did not suffer such a fate.   The most important area to the Group was to control access to privileged devices, applications and infrastructure by internal staff and third-party service providers.   Osirium looks forward to working with them closely to deliver an effective and secure interface."

 

–      Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah / Ben Maddison
Yellow Jersey PR (Financial PR) Sarah Hollins	Tel: +44 (0) 7764 947137

 

 

 

 

 

Notes to Editors:

 

About Osirium

Osirium Technologies plc (AIM: OSI.L), is a UK headquartered cyber-security Software-as-a-Service ("SaaS") provider. Osirium protects critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

 

Osirium has defined and delivered what the Directors view as the next generation PAM (Privileged Access Management) solution.  The team has developed the concept of Virtual Air Gap to separate users from passwords, with Osirium's Privileged Task Management module further strengthening Privileged Account security and delivering impressive return on investment benefits for customers.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016.  For further information please visit www.osirium.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTOKDDQABDDOKN

Close

×

RNS Number : 1759V

EU Supply PLC

01 November 2017

 

1 November 2017

EU Supply plc

("EU Supply" or the "Company" or the "Group")

 

Contract Wins and Extensions

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that it has signed two new contracts and extended two contracts in the rail and road sector.

 

Banedanmark, the Danish railroad authority, has declared its intention to award a contract to the Group, for delivery of CTMTM as SaaS and related services, of which a small part is expected to be delivered in 2017. A new smaller 4-year contract has also been signed for the Norwegian Railway Directorate.

 

Two other European rail and road authorities have extended their existing contracts with the Group, which were otherwise due to expire.

 

 

FURTHER ENQUIRIES

EU Supply plc Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, Ed Thomas

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for e-sourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUAVBRBKAROAA

Close